SYRS News and Press, Syros Pharmaceuticals Inc. From 03/30/22

Gainers: Adagio Therapeutics (ADGI) +48%. Vyant Bio (VYNT) +23%. Vir Biotechnology (VIR) +19%. Sonoma Pharmaceuticals (SNOA) +15%. Syros Pharmaceuticals (SYRS) +15%. Losers: Revelation Biosciences (REVB) -40%. UpHealth (UPH) -29%. The Valens (VLNS)...

Syros Pharmaceuticals, Inc. (SYRS) Q4 2021 Financial Results Conference Call March 15, 2022, 08:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications and Investor Relations Nancy Simonian - Chief Executive Officer Jason Haas - Chief Financial Officer David Roth - ...

Syros Pharmaceuticals press release (NASDAQ:SYRS): Q4 GAAP EPS of -$0.38 beats by $0.08. Revenue of $78M (+1268.4% Y/Y) beats by $73.16M. Cash, cash equivalents and marketable securities as of December 31, 2021 were $143.4M. The company believes that its existing cash, cash equivalents and ma...

On Track to Report PK and Safety Data from Ongoing Dose Confirmation Study of SY-2101 in Mid-2022 Expect to Report Clinical Activity from the Safety Lead-In Portions of the Ongoing SELECT-AML-1 Trial of Tamibarotene and the Expansion Cohort of SY-5609 in Pancreatic Cancer in 2...

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open. The consensus EPS Estimate is -$0.45 (+27.4% Y/Y) and the consensus Revenue Estimate is $4.84M (-15.1% Y/Y). Over the last 3 months, EPS estimates have seen 0 upwa...

ANIP, ATNX, BBI, OTCQX:CCHWF, CTRN, DOLE, DTIL, GMDA, KMDA, KNDI, KPLT, NRP, OTCPK:RWEOY, SYRS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, March 15, 2022 to report its fourth quarter and full year 2021 financial r...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on its CDK12 inhibitor program at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking...

The clinical-stage biotech, Syndax Pharmaceuticals (NASDAQ:SNDX), announced on Tuesday that Kate Madigan, M.D., will be appointed as the company’s new Chief Medical Officer, effective immediately. She will replace Michael Meyers, who will remain with the company until June before takin...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming virtual inv...